Gastric Balloon (Intragastric Balloon)

The gastric balloon is one of the most established and least invasive tools in obesity medicine — a space-occupying device placed temporarily inside the stomach to reduce its effective volume, slow gastric emptying, and prolong the feeling of fullness after meals, which helps patients eat less and lose weight (Apovian et al., The Obesity Society, 2025; Sullivan et al., Gastroenterology, 2017). Unlike bariatric surgery, a balloon requires no incisions and permanently alters no anatomy; it is removed (or, for the swallowable self-emptying balloon, passed naturally) after its treatment period, typically 4 to 6 months (Elmaleh-Sachs et al., JAMA, 2023; Silva et al., Obesity Surgery, 2024).

Intragastric balloons are FDA-approved — in conjunction with diet and exercise — for adults with a BMI of 30 to 40 who have not achieved adequate weight loss with lifestyle changes alone. This makes the balloon an option specifically for patients whose BMI of 30–35 may exclude them from traditional bariatric surgery, filling the gap between medication/lifestyle therapy and surgery (Apovian et al., The Obesity Society, 2025; Muniraj et al., AGA Clinical Practice Guidelines, 2021).

Several balloon designs have been developed, differing in how they are placed (endoscopically vs. swallowed), what they are filled with (saline vs. gas), whether their volume can be adjusted, and whether they require an endoscopy for removal. In the U.S., the FDA-approved systems now include the Orbera single saline-filled balloon (endoscopically placed and removed), the Spatz3 adjustable saline-filled balloon (endoscopically placed, with a fill volume that can be changed during therapy), and the Allurion/Elipse swallowable, self-emptying "procedureless" balloon — which is swallowed as a capsule and designed to pass naturally without any endoscopy for placement or removal. The Obalon swallowable gas-filled system is FDA-approved but has been largely withdrawn from the market, and the ReShape Duo was removed in 2018 (Apovian et al., The Obesity Society, 2025; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Telem & Ghaferi, JAMA, 2020; Silva et al., Obesity Surgery, 2024). The American Gastroenterological Association formally supports intragastric balloons as a weight-loss intervention for appropriately selected patients with obesity (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

‍

A gastric balloon works through two complementary mechanisms. First, it is space-occupying — a balloon filled with 400–700 mL of saline (or a comparable volume of gas) physically reduces the room available for food, so smaller meals produce fullness (Sullivan et al., Gastroenterology, 2017). Second, and just as importantly, it slows gastric emptying and alters stomach motility — studies show the single saline balloon delays gastric emptying by roughly 47% compared with baseline, meaning food lingers longer and satiety is prolonged between meals (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Sullivan et al., Gastroenterology, 2017).

There is also a hormonal component: balloon placement has been associated with changes in gut hormones that regulate hunger and fullness, which may contribute to reduced appetite during therapy (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022). Crucially, the balloon is a tool that works best when it is paired with a reduced-calorie diet and increased activity — it creates the physiologic conditions that make behavior change achievable, rather than replacing it (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

‍

• No incisions, no surgery, fully reversible — the balloon is placed and removed (or passed naturally) without cutting or altering anatomy, preserving all future treatment options (Elmaleh-Sachs et al., JAMA, 2023).

• A truly procedureless option — the swallowable, self-emptying Allurion/Elipse balloon requires no endoscopy and no anesthesia for either placement or removal, eliminating the risks associated with sedation (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Vantanasiri et al., Obesity Surgery, 2020).

• Meaningful short-term weight loss — roughly 10–13% total body weight loss by the end of therapy, about 2–3 times the weight loss of lifestyle changes alone (Apovian et al., The Obesity Society, 2025; McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022; Silva et al., Obesity Surgery, 2024).

• High responder rate — in randomized data, about 85% of balloon patients achieved ≥5% total body weight loss and roughly 62% achieved ≥10%, versus far lower rates with lifestyle therapy alone (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

• Outpatient and quick — placement is typically a 20–30 minute endoscopic procedure, or a brief swallow-based placement for capsule systems, with same-day discharge (Telem & Ghaferi, JAMA, 2020).

• Access for BMI 30–35 — offers a device-based option to patients who fall below the traditional surgical threshold (Apovian et al., The Obesity Society, 2025).

• Improves metabolic markers — balloon therapy lowers HbA1c and fasting glucose more than non-invasive therapy, and swallowable-balloon data also show improvement in HDL and triglycerides (Muniraj et al., AGA Clinical Practice Guidelines, 2021; Silva et al., Obesity Surgery, 2024).

• Effective bridge before surgery — used to achieve preoperative weight loss and shrink liver volume in patients with class III/super obesity, making subsequent surgery safer and technically easier (Laing et al., Digestive Diseases and Sciences, 2017).

‍

The gastric balloon is designed for adults with a BMI of 30 to 40 who have not achieved adequate weight loss with diet and exercise alone and who are willing to participate in a medically supervised weight-loss program during therapy (Muniraj et al., AGA Clinical Practice Guidelines, 2021; Laing et al., Digestive Diseases and Sciences, 2017). Ideal candidates:

• Have a BMI in the 30–40 range (the FDA-studied population; patients outside this range have not been studied in U.S. trials) (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

• Prefer a non-surgical, reversible option — and, for those who wish to avoid endoscopy and anesthesia entirely, the swallowable procedureless balloon is particularly attractive (Vantanasiri et al., Obesity Surgery, 2020).

• Have a BMI (30–35) that falls below traditional surgical criteria (Apovian et al., The Obesity Society, 2025).

• Can commit to lifestyle modification and will take a proton pump inhibitor (PPI) throughout therapy to protect against ulceration (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

• Need preoperative weight loss or liver-volume reduction as a bridge to bariatric surgery (Laing et al., Digestive Diseases and Sciences, 2017).

The balloon is contraindicated in patients with prior gastric or bariatric surgery, a large hiatal hernia (generally >2 cm), active gastric ulceration or inflammation, gastrointestinal varices, a motility disorder, increased risk of upper-GI bleeding, inability to take a PPI, pregnancy, or uncontrolled psychiatric illness or substance use disorder (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Laing et al., Digestive Diseases and Sciences, 2017).

‍

Placement depends on the balloon type. For endoscopically placed saline balloons (Orbera, Spatz3), a diagnostic upper endoscopy is first performed — typically under conscious or monitored sedation — to confirm there are no contraindications such as an ulcer or large hiatal hernia. The deflated balloon, preloaded on a thin catheter, is passed transorally into the stomach, and an endoscope is advanced alongside to confirm correct position. Under direct vision, the balloon is filled with 400–700 mL of saline (often mixed with methylene blue, a dye that turns the urine green if the balloon leaks, serving as a safety alert), the delivery catheter is detached via a self-sealing valve, and placement is confirmed (Abu Dayyeh et al., AGA Clinical Practice Update, 2017; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

For the adjustable balloon (Spatz3), the fill volume can be increased later to boost weight loss if results plateau, or decreased to relieve intolerance — this adjustability improves both tolerability and weight loss (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022).

For the swallowable procedureless balloon (Allurion/Elipse), no endoscopy and no anesthesia are needed. The patient swallows a capsule containing the deflated balloon, which remains attached to a thin catheter; correct position in the stomach is confirmed by X-ray, the balloon is filled with approximately 550 mL of fluid through the catheter, a second X-ray confirms the radiopaque valve is in place, and the catheter is then gently withdrawn through the mouth (Silva et al., Obesity Surgery, 2024; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

Removal depends on the balloon type. Endoscopic balloons (Orbera, Spatz3) are removed endoscopically at about 6 months, generally under general anesthesia to protect the airway: the balloon is punctured, the fluid is aspirated, and the deflated shell is grasped and withdrawn (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022). The Allurion/Elipse balloon is the exception — at approximately 4 months a valve spontaneously opens, the balloon empties, and it passes naturally through the GI tract, requiring neither endoscopic placement nor removal (Silva et al., Obesity Surgery, 2024; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

‍

The most common issues after balloon placement are nausea, vomiting, and abdominal pain, which are usually most intense in the first days and typically resolve with medication; abdominal pain occurs in roughly one-third of patients and nausea in about 29% (Ruban et al., Digestive Diseases and Sciences, 2018; Elmaleh-Sachs et al., JAMA, 2023). The leading reason for early balloon removal is intolerance from these symptoms — about 7.5% for the single endoscopic saline balloon, and notably lower (around 3%) for the swallowable procedureless balloon (Abu Dayyeh et al., AGA Clinical Practice Update, 2017; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022). Serious complications are infrequent — pooled serious adverse event rates are approximately 0.9% for the swallowable balloon and under 1% across balloon types — and include gastric ulceration, gastric outlet obstruction, spontaneous balloon deflation with migration, and, rarely, gastric perforation or small-bowel obstruction (Silva et al., Obesity Surgery, 2024; Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Lingvay et al., Lancet, 2024). A proton pump inhibitor is taken throughout therapy to reduce ulcer risk, and methylene blue in the fill fluid provides early warning of a leak in saline balloons (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022). General endoscopic and anesthetic risks apply to the endoscopic balloons, particularly at removal, where general anesthesia is preferred to prevent aspiration — a risk the swallowable procedureless balloon largely avoids (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

‍

Recovery is rapid because no incisions are made and no anatomy is altered. Most patients go home the same day (Telem & Ghaferi, JAMA, 2020). The first 3–7 days are typically the hardest, with nausea, cramping, and occasional vomiting as the stomach adapts to the balloon; this is managed with anti-nausea medication, acid suppression, and a staged diet beginning with clear liquids and advancing through full liquids to soft and then regular foods over about two weeks. Most patients return to normal activity within a few days. Adequate hydration and adherence to the dietary progression are the keys to getting through the adaptation period without early removal (Ruban et al., Digestive Diseases and Sciences, 2018).

‍

The gastric balloon is, by design, a temporary intervention, and setting honest expectations is essential. Peak weight loss occurs at the end of the treatment period — around 10–13% total body weight — but some weight is typically regained after the balloon is removed or passed; in the U.S. pivotal Orbera trial, 10.2% total weight loss at 6 months settled to about 7.6% six months after removal (McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022; Elmaleh-Sachs et al., JAMA, 2023). Emerging real-world data on the swallowable balloon are more encouraging when paired with structured digital follow-up — one large multicenter cohort reported that patients retained roughly 95% of the weight lost during balloon residence at one year after natural passage, under app- and connected-scale–based monitoring (Tinoco Ortiz et al., Obesity Surgery, 2026). Even so, longer-term data across balloon types remain sobering without ongoing therapy, with weight tending to return over years (Chan et al., Obesity Surgery, 2021).

The clear lesson from the evidence is that durable results depend on what happens around and after the balloon — continued dietary intensity, behavioral support, anti-obesity medication, and in some cases repeat balloon or a definitive procedure. Patients who maintain a moderate-to-high-intensity diet after removal can continue to lose weight, while those who return to prior habits regain it (Muniraj et al., AGA Clinical Practice Guidelines, 2021; Sullivan et al., Gastroenterology, 2017). The balloon is best understood as a powerful 4- to 6-month "jump-start" that must be embedded in a long-term obesity-management plan — not a standalone cure.

‍

More in Endoscopic Weight-Loss Procedures

Related procedures: Allurion Balloon, Endoscopic Balloon Removal, Transoral Outlet Reduction, Medical Weight Loss Program, Orbera Intragastric Balloon. For an overview of all options, see Endoscopic Sleeve Gastroplasty.

Conditions treated: Obesity, Overweight, Weight Regain, Metabolic Adaptation.

Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, has been performing bariatric endoscopy since 2007 with the early ROSE Procedures, the precursor to the ESG. His clinical experience is buoyed by his research experience, which has had him serve as a Principal Investigator for 6 different bariatric endoscopic FDA pivotal trials. He was one of the early physician adopters of gastric balloons after they were FDA approved in 2015.

Dr. de la Cruz-Muñoz is board certified in metabolic and bariatric surgery and provides the full range of weight-loss care, from endoscopic options such as TORe and ESG to primary and revision surgery. Balloon candidates therefore get an unbiased, individualized recommendation and a seamless route to ESG or surgical treatment if their needs change over time.

Balloon patients benefit from a physician who also performs surgery: Dr. de la Cruz-Muñoz has over 25 years in bariatric surgery and more than 9,000 bariatric operations, a volume few surgeons reach.

• Single saline balloon (Orbera), U.S. pivotal trial: 10.2% TBWL at 6 months vs 3.3% for lifestyle alone; ~7.6% at 12 months (6 months after removal) (Elmaleh-Sachs et al., JAMA, 2023; McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022).

• Adjustable balloon (Spatz3): among the highest of the balloon types — multicenter data report roughly 15–16% TBWL, attributed to volume adjustability that both improves tolerance and allows up-titration (McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022).

• Swallowable procedureless balloon (Allurion/Elipse): pooled ~12.5% TBWL by the end of the ~4-month treatment period across 1,600+ patients, with real-world cohorts reporting ~14% TWL at 4 months and substantial retention at one year under structured virtual follow-up (Silva et al., Obesity Surgery, 2024; Tinoco Ortiz et al., Obesity Surgery, 2026).

• Swallowable gas-filled balloon (Obalon): ~6.6% TBWL at 24 weeks in the SMART trial, with 88.5% weight-loss maintenance at 48 weeks (Apovian et al., The Obesity Society, 2025).

These are averages; individual results vary with balloon type, adherence to diet and activity, and whether adjunctive therapy is used.

‍

Weight loss from balloon therapy drives measurable short-term improvement in metabolic health. Across randomized and observational data, intragastric balloons lower HbA1c and fasting blood glucose more than non-invasive therapy alone, with the greatest benefit seen in patients who start with a fasting glucose >100 mg/dL, an HbA1c >6.5%, or a BMI >40 (Muniraj et al., AGA Clinical Practice Guidelines, 2021). Swallowable-balloon data additionally show improvement in HDL and triglycerides, and real-world cohorts report reductions in HbA1c, systolic blood pressure, and LDL cholesterol at 12 months (Silva et al., Obesity Surgery, 2024; Tinoco Ortiz et al., Obesity Surgery, 2026). Most patients who reach the ~10% total-weight-loss threshold can expect improvement in obesity-related conditions such as hypertension, dyslipidemia, and glycemic control; however, as with weight, sustaining these metabolic gains after the balloon is removed requires ongoing lifestyle or pharmacologic management.

‍

Because weight regain after balloon removal is the central challenge, relapse prevention is built into the treatment from day one. The evidence supports: (1) high-intensity dietary intervention during and after therapy — patients on a more intensive diet continued losing weight even after removal, while low-intensity dieters did not (Muniraj et al., AGA Clinical Practice Guidelines, 2021); (2) structured digital/telemonitoring follow-up, which with the swallowable balloon has been associated with retaining the large majority of weight lost a year after balloon passage (Tinoco Ortiz et al., Obesity Surgery, 2026); (3) adding anti-obesity medication such as a GLP-1 agonist to extend and deepen weight loss in patients with a suboptimal response (Lopez-Nava et al., Obesity Surgery, 2020); and (4) transition to maintenance therapy — lifestyle, medication, or sequential/repeat endoscopic therapy — after removal, reflecting the modern "continuum of care" model in which balloons, medications, and surgery are used together or in sequence.

‍

Reflux is an important consideration with gastric balloons. By occupying space and slowing gastric emptying, a balloon can provoke or worsen acid reflux and heartburn, and a large hiatal hernia (generally >2 cm) is a contraindication to placement precisely because it predisposes to reflux complications (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022; Laing et al., Digestive Diseases and Sciences, 2017). For this reason, a proton pump inhibitor is prescribed throughout the entire treatment period — both to control reflux symptoms and to protect the gastric lining from ulceration caused by the balloon pressing against the stomach wall (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022). Pre-existing reflux and hiatal hernia are screened for before placement, and for the adjustable balloon the fill volume can be reduced if reflux symptoms become problematic (McCarty & Thompson, Yamada's Textbook of Gastroenterology, 2022). Patients with severe or erosive reflux may be better served by a reflux-protective surgical option such as gastric bypass.

‍

The gastric balloon is a temporary, anatomy-preserving therapy, so it leaves every future option open. After a balloon course, the typical next steps — individualized to the patient's response and goals — include:

• Repeat balloon therapy — a second balloon can be placed after an interval, since no anatomy is altered (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

• Balloon plus anti-obesity medication — adding a GLP-1 agonist or other agent to extend and deepen weight loss (Lopez-Nava et al., Obesity Surgery, 2020).

• Endoscopic sleeve gastroplasty (ESG) — a more durable, still-incisionless endoscopic option (Elmaleh-Sachs et al., JAMA, 2023).

• Bariatric surgery (sleeve gastrectomy or gastric bypass) — the definitive, most durable option for patients who need more than a balloon can provide; the balloon is frequently used first as a safe bridge to surgery in high-BMI patients (Laing et al., Digestive Diseases and Sciences, 2017).

‍

As with any weight-loss intervention, the goal of balloon therapy is loss of fat mass while protecting lean muscle. Because the balloon reduces overall food intake, patients are counseled to prioritize adequate protein at every meal and to combine aerobic activity with resistance (strength) training throughout the treatment period, so that weight lost comes preferentially from fat rather than metabolically active muscle. Tracking progress by body composition (fat mass, muscle mass) rather than the scale alone gives a truer picture of success and helps protect the resting metabolic rate that guards against regain after the balloon is removed.

Gastric balloon therapy is frequently considered elective and is often not covered by insurance, as many payers classify intragastric balloons as investigational or exclude non-surgical weight-loss devices; coverage, when it exists, varies widely by plan. Qualification generally mirrors the FDA indication: a documented BMI of 30–40, failure to achieve adequate weight loss with diet and exercise, enrollment in a medically supervised weight-management program, and absence of contraindications (prior gastric surgery, large hiatal hernia, active ulcer, inability to take a PPI) (Muniraj et al., AGA Clinical Practice Guidelines, 2021; Laing et al., Digestive Diseases and Sciences, 2017). Many patients pay out of pocket; specific coverage, documentation, and any pre-authorization requirements should be confirmed with each individual plan.

• Diagnostic upper endoscopy (for endoscopic systems) to confirm candidacy and exclude ulcer, large hiatal hernia, or other contraindications; the swallowable procedureless balloon does not require endoscopy for placement, though screening for contraindications is still performed (Abu Dayyeh et al., AGA Clinical Practice Update, 2017; Silva et al., Obesity Surgery, 2024).

• Start a proton pump inhibitor before and throughout treatment to protect the stomach lining and control reflux (Jirapinyo & Thompson, Digestive Diseases and Sciences, 2022).

• Enrollment in a supervised diet-and-lifestyle program, which is part of the FDA-approved indication (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

• Standard pre-procedure fasting, plus pre-anesthesia evaluation for endoscopically placed balloons (Abu Dayyeh et al., AGA Clinical Practice Update, 2017).

• Medication review and counseling on realistic expectations, the temporary nature of therapy, and the post-removal maintenance plan.

‍

Nutrition after placement follows a staged progression to let the stomach adapt to the balloon: clear liquids for the first 1–2 days, advancing to full liquids, then pureed/soft foods, and finally regular textures over roughly two weeks. Throughout therapy, the emphasis is on small portions, slow and thorough chewing, separating liquids from solids, and prioritizing protein and hydration to preserve lean mass and prevent dehydration during the nausea-prone early phase. A high-intensity, reduced-calorie dietary plan maintained during and especially after the balloon course is the single most important factor in converting short-term loss into lasting results (Muniraj et al., AGA Clinical Practice Guidelines, 2021).

Because the balloon is incisionless, there are no lifting or wound restrictions, and most patients resume normal activity within a few days once early nausea subsides. Walking and light activity are encouraged immediately. A structured program combining aerobic exercise with resistance (strength) training at least twice weekly is reintroduced as tolerated and is specifically encouraged to preserve muscle mass and protect metabolic rate during active weight loss — habits that must continue after the balloon is removed to prevent regain.

For international patients, the choice of balloon matters. A swallowable balloon that passes naturally needs no removal visit, while endoscopic balloons need a second procedure about six months later. Discuss your travel plans at the virtual consultation so we can recommend the most practical option.